

Taking a new approach:

Therapeutic options for highly treatment-experienced HIV-1 patients


Theratechnologies Symposium
Wednesday 27 October 2021, 16:15–17:15 BST
18th European AIDS Conference (EACS)

Join us for an exciting, expert-led symposium titled 'Taking a new approach: Therapeutic options for highly treatment-experienced HIV-1 patients'.

Throughout this session we will explore the challenges of highly treatment-experienced patients with HIV-1, focusing on treatment and highlighting the pathophysiology and impact of reduced susceptibility on virological failure and rebound.

We will also consider the management of these patients from the virologist and pharmacologist perspectives, discussing both the mechanism of action and virologic characteristics of newly available treatments, and the impact of drug-drug interactions on creating effective optimised background regimens.

We look forward to welcoming you to this symposium.



This symposium is fully sponsored and supported by Theratechnologies Europe Limited, including speaker honoraria and production of materials, and may include promotional messages related to Theratechnologies products.

THERA
technologies

Taking a new approach:

Therapeutic options for highly treatment-experienced HIV-1 patients

TIME	PRESENTATION	PRESENTER
16:15–16:20	Welcome and introductions	Dr Graeme Moyle (Chair) Chelsea and Westminster Hospital, London, United Kingdom
16:20–16:35	Understanding the challenges of highly treatment-experienced HIV-1 patients	Prof. Antonella Castagna San Raffaele Hospital, Milan, Italy
16:35–16:50	A virologist's perspective on management	Prof. Anne-Geneviève Marcelin Sorbonne University & Pitié-Salpêtrière Hospital, Paris, France
16:50–17:05	Building an optimised regimen: The impact of drug-drug interactions	Prof. David Back University of Liverpool, Liverpool, United Kingdom
17:05–17:15	Discussion and Q&A	All faculty Q&A facilitated by Dr Graeme Moyle (Chair)

For more information, visit us at the Theratechnologies booth.

This symposium is fully sponsored and supported by Theratechnologies Europe Limited, including speaker honoraria and production of materials, and may include promotional messages related to Theratechnologies products.

Prescribing information
can be found here:



Ibalizumab 5mPC

<https://www.ema.europa.eu/en>

Legal category: POM

Price (TBD)

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to +49 (0) 30 3119 6151 or medinfo.eu@theratech.com